Bladder cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• HER2 47
• PD-1 18
• PD-L1 10
• FGFR 10
• PI3K 1
• TP53 1
• AKT 0
• mTOR 0
• STAT3 0
• MAPK 0
• PPAR 0
• CTNNB1 0
• TROP2 1
• EGFR 0
• ERK 0
• MYC 0
• AMPK 0
• CTLA-4 1
• PTEN 0
• VEGF 4
• STING 0
• GPX4 0
• MMP-9 0
• BCL-2 0
• YAP 0
• IL-6 0
• JAK 0
• NRF2 0
• PSMA 1
• AR 0
• B7-H3 0
• CDK4/6 1
• HIF-1 0
• HSP90 0
• IL-15 1
• JNK 0
• PARP 0
• ALK 0
• ARID1A 2
• BRCA1 1
• COX-2 0
• HDAC 1
• IDH 1
• KRAS 0
• LAG-3 0
• METTL3 1
• PIK3CA 0
• PKM2 0
• SGLT2 0
• TERT 0
• AXL 0
• BRAF 1
• BRCA2 1
• EZH2 0
• FAK 0
• FTO 0
• GLP-1 0
• HMGB1 0
• IDO1 0
• MDM2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 61+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

  NCT05242822· Kinnate Biopharma· Updated 7 May 2025

  “Due to a change in the Sponsor's corporate strategy the study was terminated early by the Sponsor prior to enrollment into the dose expansion part of the study (Part B).”Registry text, quoted unchanged. Source

• Terminated

  Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer

  NCT04228042· M.D. Anderson Cancer Center· Updated 1 Jan 2025

  “Drug manufacturer made the business decision to cease all infigratinib oncology research in the US and withdrew the IND”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Janssen Research & Development, LLC· Source

• A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer

  NCT05567185· Janssen Pharmaceutical K.K.· Source

• A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

  NCT06919965· Janssen Research & Development, LLC· Source

• A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alterations.

  2023-507684-19-00· Janssen Cilag International· Source

• A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer

  NCT07827612· Eli Lilly and Company· Source

• A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Eli Lilly and Company· Source

• Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

  NCT04963153· National Cancer Institute (NCI)· Source

• A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

  NCT04917809· Memorial Sloan Kettering Cancer Center· Source

• A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

  NCT04172675· Janssen Research & Development, LLC· Source

• A Phase 2 Clinical Study of ABSK061 and ABSK043

  NCT06632262· Abbisko Therapeutics Co, Ltd· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 11
• Mendelian Randomization Analysis 15
• CRISPR-Cas Systems 14
• Gene Expression Profiling 78
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 7
• Exome Sequencing 3
• Proteomics 27
• Metabolomics 15
• Mass Spectrometry 4
• Flow Cytometry 17
• Immunohistochemistry 93
• Liquid Biopsy 23
• Circulating Tumor DNA 33
• Xenograft Model Antitumor Assays 76
• Positron-Emission Tomography 10
• Magnetic Resonance Imaging 40
• Machine Learning 44
• Deep Learning 24
• Cohort Studies 76
• Genome-Wide Association Study 18

• Deep learning-based multiomics integration identifies AI-defined tissue regions associated with cancer-associated fibroblast enrichment and chemoresistance in muscle-invasive bladder cancer.

  Funct Integr Genomics, Oct 2026

• Task-agnostic explainable contrastive learning model for malignant cell detection in urine cytology.

  Biomed Phys Eng Express, Sept 2026

• Deep Learning-Assisted Accuracy Improvement in Bladder Cancer Staging of Spectrum-Aided Visual Enhanced Cystoscopy Images.

  Biosensors (Basel), Aug 2026

• Deep learning-based automated identification of papillary bladder cancer from endoscopic still images using SE-ResNeXt-50.

  World J Urol, Aug 2026

• Deep learning-assisted detection of lymph node metastases in bladder cancer.

  Diagn Pathol, Aug 2026

• MRICombo: a deep-learning-based framework for universal volumetric segmentation grading-staging and malignancy detection across heterogeneous MRI.

  Nat Commun, Aug 2026

• UCtracker: A Deep Learning-Based DNA Methylation Model for Noninvasive Diagnosis and Recurrence Surveillance of Urothelial Carcinoma in a Prospective Study.

  Adv Sci (Weinh), Aug 2026

• Deep learning approaches for predicting response to neoadjuvant chemotherapy in muscle invasive bladder cancer: A systematic review.

  Urol Oncol, Jul 2026

• Accurate focal-plane selection is crucial for artificial intelligence assessment of three-dimensional urine cytology specimens for bladder cancer screening and surveillance.

  Cancer Cytopathol, Jul 2026

• [MRI-based deep learning model for preoperative prediction of urothelial carcinoma with variant histology of bladder: a retrospective, multicenter study].

  Zhonghua Wai Ke Za Zhi, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.